Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 20/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 14/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.75 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30383032 | 1.00 | CHRM4 (0.75) | CHRM4CHRM2CYP3A4CYP1A2CYP2B6 | |
| SCHEMBL23499308 | 1.00 | CHRM4 (0.75) | CHRM4CHRM2CYP3A4CYP1A2CYP2B6 | |
| SCHEMBL30382733 | 1.00 | CHRM4 (0.75) | CHRM4CHRM2CYP3A4CYP1A2CYP2B6 | |
| SCHEMBL25508073 | 0.92 | CHRM4 (0.75) | CHRM4CHRM2CYP3A4CYP1A2CYP2B6 | |
| SCHEMBL30382445 | 0.86 | CHRM4 (1.00) | CHRM4CHRM2CYP3A4CYP1A2CYP2B6 | |
| SCHEMBL25264831 | 0.86 | CHRM4 (1.00) | CHRM4CHRM2CYP3A4CYP1A2CYP2B6 | |
| SCHEMBL25191968 | 0.86 | CHRM4 (1.00) | CHRM4CHRM2CYP3A4CYP1A2CYP2B6 | |
| SCHEMBL30382350 | 0.83 | CHRM4 (0.93) | CHRM4CHRM2CYP3A4CYP1A2CYP2B6 | |
| SCHEMBL25193974 | 0.83 | CHRM4 (0.93) | CHRM4CHRM2CYP3A4CYP1A2CYP2B6 | |
| SCHEMBL25193969 | 0.83 | CHRM4 (0.93) | CHRM4CHRM2CYP3A4CYP1A2CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150986-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-05-18 | — | — | US | claimed |
| WO-2021119265-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-06-17 | — | — | WO | claimed |
| US-20230150986-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-05-18 | — | — | US | disclosed |
| US-20230150986-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-05-18 | — | — | US | disclosed |
| US-20230150986-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150986-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | CHRM4 3/4885CHRM2 2/4885CYP3A4 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.